An orally bioavailable pyrrolopyrimidinylurea compound that simultaneously binds to both the adenine and the adjacent hydrophobic pocket of the inactive form of VEGFR2 with high-affinity (type-II inhibitor) and acts as a pseudo-irreversible inhibitor with prolonged action. Shown to potently inhibit the activities of VEGFR2, VEGFR1, Tie-2, PDGFRa, PDGFRb and c-kit (IC50=6.2, 15, 20, 35, 96 and 170nM, respectively) with moderate to excellent selectivity over B-raf and Aurora-A (IC50=0.9 and 1.05uM) and FGFR1, HER2, EGFR, IR, PKCth (>10uM) among 18-kinases. Arrests VEGF-induced HUVECs proliferation (IC50=4.4uM) and suppresses DU145 carcinoma growth in a xenograft nude mouse model (6mg/kg, b.i.d.). Formula: C21H15F4N5O2 Molecular Weight: 445.4 Solubility: DMSO (100mg/ml) Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile buffer or dH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Molekulargewicht:
445.4
Reinheit:
~95% (HPLC)
Formulierung:
Supplied as a light beige solid.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten